Rhode Island 2025 Regular Session

Rhode Island Senate Bill S0683 Compare Versions

Only one version of the bill is available at this time.

Old	New	Differences
1	1
2	2
3	3
4	4
5	5	2025 -- S 0683
6	6	========
7	7	LC001783
8	8	========
9	9	S T A T E O F R H O D E I S L A N D
10	10	IN GENERAL ASSEMBLY
11	11	JANUARY SESSION, A.D. 2025
12	12	____________
13	13
14	14	A N A C T
15	15	RELATING TO BUSINESSES AND PROFESSIONS -- COLLABORATIVE PHARM ACY
16	16	PRACTICE
17	17	Introduced By: Senators Valverde, Lauria, Murray, Thompson, and Appollonio
18	18	Date Introduced: March 07, 2025
19	19	Referred To: Senate Health & Human Services
20	20
21	21
22	22	It is enacted by the General Assembly as follows:
23	23	SECTION 1. Sections 5-19.2-2 and 5-19.2-5 of the General Laws in Chapter 5-19.2 entitled 1
24	24	"Collaborative Pharmacy Practice" are hereby amended to read as follows: 2
25	25	5-19.2-2. Definitions. 3
26	26	When used in this chapter, the following words and phrases are construed as follows: 4
27	27	(a)(1) “Collaborative pharmacy practice” is that means the practice of pharmacy whereby 5
28	28	one or more licensed pharmacist(s), with advanced training and experience relevant to the scope of 6
29	29	collaborative practice, agrees to work in collaboration with one or more physicians providers for 7
30	30	the purpose of drug therapy management of patients, such management to be pursuant to a protocol 8
31	31	or protocols written agreement authorized by the physician(s) provider(s) and subject to conditions 9
32	32	and limitations as set forth by the department. A healthcare professional who has prescribing 10
33	33	privileges and is employed with or by a collaborating physician provider may be in such an 11
34	34	agreement. 12
35	35	(b)(2) “Collaborative practice agreement” means a written and signed agreement, entered 13
36	36	into voluntarily, between one or more licensed pharmacist(s), with advanced training and 14
37	37	experience relevant to the scope of collaborative practice, and one or more physicians referring 15
38	38	providers that defines the collaborative pharmacy practice in which the pharmacist(s) and 16
39	39	physician(s) provider(s) who are parties to the agreement propose to engage. Collaborative practice 17
40	40	agreements shall be made in the best interest of public health, follow clinical guidelines and 18
41	41
42	42
43	43	LC001783 - Page 2 of 4
44	44	standards of care, and be agreed upon guidance with the collaborating provider. Collaborative 1
45	45	practice agreements shall be submitted to the board of pharmacy for record-keeping purposes. No 2
46	46	approval or denial process shall be required, and parties to the collaborative practice agreement 3
47	47	may begin acting pursuant to the agreement when all required documentation is complete. It shall 4
48	48	be the responsibility of the parties to the collaborative practice agreement to respond to the board’s 5
49	49	inquiries and clarify all issues pertinent to the collaborative practice agreement. Collaborative 6
50	50	practice agreements shall be reviewed and signed by the parties thereto annually, and refiled for 7
51	51	record keeping with the board if substantive changes that impact patient care are made. 8
52	52	(c) “Collaborative practice committee” shall consist of six (6) individuals: three (3) 9
53	53	individuals to be appointed by the board of pharmacy from nominees provided by the Rhode Island 10
54	54	Pharmacists Association and three (3) individuals to be appointed by the board of medical licensure 11
55	55	and discipline from nominees provided by the Rhode Island Medical Society. The collaborative 12
56	56	practice committee shall advise the director on all issues pertinent to the regulation of collaborative 13
57	57	practice agreements. 14
58	58	(d)(3) “Drug therapy management” means the review, in accordance with a collaborative 15
59	59	practice agreement, of drug therapy regimen or regimens of patients by one or more licensed 16
60	60	pharmacist(s) for the purpose of initiating, adjusting, monitoring, or discontinuing the regimen. 17
61	61	Decisions involving drug therapy management shall be made in the best interests of the patient. In 18
62	62	accordance with a collaborative practice agreement, drug therapy management may include: 19
63	63	(1)(i) Initiating, adjusting, monitoring, or discontinuing drug therapy; 20
64	64	(2)(ii) Collecting and reviewing patient histories; 21
65	65	(3)(iii) Obtaining and checking vital signs, including pulse, height, weight, temperature, 22
66	66	blood pressure, and respiration, or other clinical information as appropriate or necessary to provide 23
67	67	care; and 24
68	68	(4)(iv) Under the supervision of, or in direct consultation with, one or more physician(s), 25
69	69	ordering and evaluating the results of laboratory tests directly related to drug therapy when 26
70	70	performed in accordance with approved protocols applicable to the practice setting and providing 27
71	71	such evaluation does not include any diagnostic component. 28
72	72	(e)(4) “Limited-function test” means those tests listed in the federal register under the 29
73	73	Clinical Laboratory Improvement Amendments of 1988 (CLIA) as waived tests. For the purposes 30
74	74	of this chapter, limited-function test shall include only the following: blood glucose, hemoglobin 31
75	75	A1c, cholesterol tests, and/or other tests that are classified as waived under CLIA and are approved 32
76	76	by the United States Food and Drug Administration for sale to the public without a prescription in 33
77	77	the form of an over-the-counter test kit. 34
78	78
79	79
80	80	LC001783 - Page 3 of 4
81	81	(f)(5) “Pharmacist with advanced training and experience relevant to the scope of 1
82	82	collaborative practice” means a licensed pharmacist in this state with a bachelor of science in 2
83	83	pharmacy and postgraduate educational training or a doctor of pharmacy degree. Such training shall 3
84	84	include, but not be limited to, residency training; board certification; certification from an 4
85	85	accredited professional organization educational institution; or any other continuing education 5
86	86	provider approved by the director of health collaborating provider relevant to the proposed scope 6
87	87	of the collaborative practice agreement. 7
88	88	(g)(6) “Practice of pharmacy” means the interpretation, evaluation, and implementation of 8
89	89	medical orders, including the performance of clinical laboratory tests, provided such testing is 9
90	90	limited to limited-function tests as defined herein; the dispensing of prescription drug orders; 10
91	91	participation in drug and device selection; drug regimen reviews and drug or drug-related research; 11
92	92	provision of patient counseling and the provision of those acts or services necessary to provide 12
93	93	pharmaceutical care; drug therapy management pursuant to a collaborative practice agreement; and 13
94	94	the responsibility for the supervision for compounding and labeling of drugs and devices (except 14
95	95	labeling by a manufacturer, repackager, or distributor of nonprescription drugs and commercially 15
96	96	packaged legend drugs and devices); proper and safe storage of drugs and devices; and maintenance 16
97	97	of proper records for them. 17
98	98	5-19.2-5. Immunity. 18
99	99	The director of health, board members, the collaborative practice committee, and their 19
100	100	agents and employees shall be immune from suit in any action, civil or criminal, based on any 20
101	101	disciplinary proceeding or other official act performed in good faith in the course of their duties 21
102	102	under this chapter. There shall be no civil liability on the part of, or cause of action of any nature 22
103	103	against, the board, director, their agents or their employees or against any organization or its 23
104	104	members, peer-review board or its members, or other witnesses and parties to board proceedings 24
105	105	for any statements made in good faith by them in any reports, communications, or testimony 25
106	106	concerning an investigation by the board of the conduct or competence of any licensee under this 26
107	107	chapter. 27
108	108	SECTION 2. This act shall take effect on July 1, 2025. 28
109	109	========
110	110	LC001783
111	111	========
112	112
113	113
114	114	LC001783 - Page 4 of 4
115	115	EXPLANATION
116	116	BY THE LEGISLATIVE COUNCIL
117	117	OF
118	118	A N A C T
119	119	RELATING TO BUSINESSES AND PROFESSIONS -- COLLABORATIVE PHAR MACY
120	120	PRACTICE
121	121	***
122	122	This act would expand the existing law regarding collaborative practice agreements 1
123	123	between pharmacists and physicians to allow other healthcare providers to enter into such 2
124	124	agreements. This act would also remove the definition of “collaborative practice committee,” and 3
125	125	would require submission of the collaborative practice agreements to the board of pharmacy for 4
126	126	record-keeping purposes. 5
127	127	This act would take effect on July 1, 2025. 6
128	128	========
129	129	LC001783
130	130	========
131	131